What changed?
A sourced timeline of research records and material development changes tracked by BACToBasics for CagriSema. Research-publication dates and clinical-development event dates are labeled separately so they are not mistaken for the same type of update.
Tracked items
2
Research sources
0
Development entries
2
Latest recorded date
Feb 23, 2026
Latest development activity
Feb 23, 2026 · Trial readout · U.S. FDA review
Novo Nordisk reported 23% weight loss under the trial efficacy estimand, but CagriSema did not meet the primary non-inferiority endpoint versus tirzepatide in REDEFINE 4.
Open source ↗Tracked timeline
Development changes are dated to the underlying milestone. Research-source entries use the study or source publication year currently stored in the Research Library; that year is not presented as the date BACToBasics added the record.
Trial readout · U.S. FDA review
Novo Nordisk reported 23% weight loss under the trial efficacy estimand, but CagriSema did not meet the primary non-inferiority endpoint versus tirzepatide in REDEFINE 4.
Regulatory submission · U.S. FDA review · United States
Novo Nordisk submitted a New Drug Application to the FDA for the fixed-dose cagrilintide/semaglutide combination for chronic weight management.
Following a compound creates a clean baseline from the updates currently known. When BACToBasics later records a new research source or material development change, the My Tools update badge can surface it as new for you.
BACToBasics provides educational research organization only. A development milestone does not predict future approval, and a research record does not establish that a compound is safe, effective, approved, or appropriate for use.